Stockshaven Investments Ready To Profile Provectus (OTC:PVCT)
StocksHaven Investments has announced that a profile on Provectus Pharmaceuticals will be available on 9/15/09 within the company’s website, www.StocksHaven.com. The profile will analyze the product pipeline, target market potentials, revenue streams, the management team and much more. Provectus is a unique company which is targeting the deadliest forms of cancers – melanoma, liver, and breast – while eliminating their side effects. They have had a very busy year-to-date, with a lot of positive, and successful clinical trials. The company has also received a strong buy signal from analysts according to Yahoo Finance, finance.yahoo.com/q/ao?s=PVCT.OB.
About Provectus Pharmaceuticals
Provectus Pharmaceuticals, Inc., a development stage company, specializes in oncology and dermatology therapies. The company is conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for psoriasis and atopic dermatitis. It received orphan drug designation from the FDA for its melanoma indication. In addition to its suite of proprietary drugs, Provectus Pharmaceuticals developed various intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.
Disclosure: Position in PVCT
About StocksHaven Investments
StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes
, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.
For more financial and investment news, visit www.StocksHaven.com
Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
- Contact Information
- Michael Vlaicu
- Founder and Lead Investment Analyst
- StocksHaven Investments
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.